Organogenesis Holdings Inc. (ORGO) Stock Price & Analysis
Organogenesis Holdings Inc. (ORGO) rose 4.20% to USD 2.48 as of June 10, 2026 at 03:29 UTC, according to Nexqual real-time market data.
ORGO last closed at USD 2.38; the session ranged USD 2.38–2.53 on volume of 518,349 shares. Market capitalization is $319.11M, with a 52-week range of USD 2.04–7.08 (NCM). Source: Nexqual, June 10, 2026 at 03:29 UTC.
Key Statistics (as of June 10, 2026 at 03:29 UTC)
| Price | USD 2.48 |
|---|---|
| Change | ▲ 4.20% (up) |
| Previous Close | USD 2.38 |
| Open | USD 2.38 |
| Day Range | USD 2.38 – 2.53 |
| 52-Week Range | USD 2.04 – 7.08 |
| Volume | 518,349 shares |
| Market Cap | $319.11M |
| Exchange | NCM |
Technical Analysis (ORGO)
Nexqual's technical model rates ORGO "NEUTRAL" based on 2 bullish and 3 bearish signals across 124 daily candles, as of June 10, 2026 at 03:29 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 50.66 (neutral) |
| vs SMA50 | Above (USD 2.45) |
| MACD | -0.02 (negative) |
Analyst Ratings (ORGO)
Wall Street analysts rate ORGO "Hold" based on 1 analysts, with a mean price target of USD 3 (range USD 3–3), per Nexqual as of June 10, 2026 at 03:29 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 3 |
| High Target | USD 3 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 0 / 2 / 0 |
Earnings (ORGO)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.35 |
| Revenue Estimate | $54.27M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.34 vs est -0.29 ▼ miss |
| 2025-12-31 | USD 0.4 vs est 0.21 ▲ beat |
| 2025-09-30 | USD 0.18 vs est 0.07 ▲ beat |
| 2025-06-30 | USD -0.06 vs est -0.01 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:29 UTC.
Financials & Fundamentals (ORGO)
| Total Revenue | $514.70M |
|---|---|
| Revenue Growth (YoY) | -57.10% |
| Gross Margin | +73.89% |
| Operating Margin | -174.69% |
| Profit Margin | +0.53% |
| ROE | +0.73% |
| Debt / Equity | 18.58 |
| Current Ratio | 3.53 |
| Total Cash | $91.38M |
| Total Debt | $70.86M |
| Free Cash Flow | $21.21M |
Source: Nexqual, June 10, 2026 at 03:29 UTC.
Financial Health Score (ORGO)
Nexqual rates Organogenesis Holdings Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:29 UTC.
| Growth | Strong — Revenue +17% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $91M cash vs $71M debt, net cash position |
| Cash Flow | Mixed — FCF $21M, slim 3.8% margin |
| Efficiency | Weak — ROE 1%, ROA 2.1% |
Ownership (ORGO)
| Insider Ownership | +47.46% |
|---|---|
| Institutional Ownership | +49.79% |
| Shares Outstanding | 128.67M |
| Float | 57.38M |
| Short % of Float | +16.25% |
Source: Nexqual, June 10, 2026 at 03:29 UTC.
Leadership (ORGO)
Organogenesis Holdings Inc. is led by Gary S. Gillheeney (age 70), President, CEO, Chair of the Board, per Nexqual as of June 10, 2026 at 03:29 UTC.
| President, CEO, Chair of the Board | Gary S. Gillheeney (age 70) |
|---|---|
| Chief Financial Officer | David C. Francisco (age 59) |
| Chief Operating Officer | Patrick Bilbo (age 63) |
Major Backers & Investors (ORGO)
Notable institutional backers of Organogenesis Holdings Inc. include Morgan Stanley, Soleus Capital Management, L.P., First Light Asset Management, LLC, according to Nexqual as of June 10, 2026 at 03:29 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 9.03% |
| Soleus Capital Management, L.P. | 7.84% |
| First Light Asset Management, LLC | 2.72% |
| Shaw D.E. & Co., Inc. | 1.79% |
| Assenagon Asset Management S.A. | 1.53% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 5.52% |
| Vanguard Group | 4.84% |
| Dimensional Fund Advisors | 2.55% |
| Geode Capital | 1.39% |
| Deutsche Bank AG | 1.33% |
Source: Nexqual, June 10, 2026 at 03:29 UTC.
From Organogenesis Holdings Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States.
- The company also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; and TransCyte, a bioengineered tissue scaffold that promotes burn healing.
- In addition, it develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products.
- The company serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PTGX | Protagonist Therapeutics, Inc. | USD 105.87 | ▲ 8.72% |
| STRO | Sutro Biopharma, Inc. | USD 25.79 | ▼ 1.15% |
| FULC | Fulcrum Therapeutics, Inc. | USD 3.52 | ▼ 4.61% |
| ACRS | Aclaris Therapeutics, Inc. | USD 4.3 | ▼ 1.38% |
| SLDB | Solid Biosciences Inc. | USD 6.57 | ▼ 1.94% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:29 UTC. This page is informational and not investment advice.